Literature DB >> 23121542

Mechanistic and computational studies of exocyclic stereocontrol in the synthesis of bryostatin-like cis-2,6-disubstituted 4-alkylidenetetrahydropyrans by Prins cyclization.

Yasuyuki Ogawa1, Phillip P Painter, Dean J Tantillo, Paul A Wender.   

Abstract

The Prins cyclization of syn-β-hydroxy allylsilanes and aldehydes gives cis-2,6-disubstituted 4-alkylidenetetrahydropyrans as sole products in excellent yields regardless of the aldehyde (R″) or syn-β-hydroxy allylsilane substituent (R') used. By reversing the R″ and R' groups, complementary exocyclic stereocontrol can be achieved. When the anti-β-hydroxy allylsilanes are used, the Prins cyclization gives predominantly cis-2,6-disubstituted 4-alkylidenetetrahydropyrans, now with the opposite olefin geometry in excellent yield. The proposed reaction mechanism and the observed stereoselectivity for these processes are supported by DFT calculations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23121542      PMCID: PMC3537866          DOI: 10.1021/jo301953h

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  59 in total

1.  Total synthesis of the cyanolide A aglycon.

Authors:  Michael R Gesinski; Scott D Rychnovsky
Journal:  J Am Chem Soc       Date:  2011-06-08       Impact factor: 15.419

2.  Racemization in Prins cyclization reactions.

Authors:  Ramesh Jasti; Scott D Rychnovsky
Journal:  J Am Chem Soc       Date:  2006-10-18       Impact factor: 15.419

Review 3.  Protein kinase C activators as synaptogenic and memory therapeutics.

Authors:  Miao-Kun Sun; Daniel L Alkon
Journal:  Arch Pharm (Weinheim)       Date:  2009-12       Impact factor: 3.751

4.  Synthesis of reblastatin, autolytimycin, and non-benzoquinone analogues: potent inhibitors of heat shock protein 90.

Authors:  Iwona E Wrona; Alexander Gozman; Tony Taldone; Gabriela Chiosis; James S Panek
Journal:  J Org Chem       Date:  2010-05-07       Impact factor: 4.354

5.  Enantioselective total synthesis of (-)-zampanolide, a potent microtubule-stabilizing agent.

Authors:  Arun K Ghosh; Xu Cheng
Journal:  Org Lett       Date:  2011-07-12       Impact factor: 6.005

6.  Aromatic 4-tetrahydropyranyl and 4-quinuclidinyl cations. Linking Prins with Cope and Grob.

Authors:  Roger W Alder; Jeremy N Harvey; Mark T Oakley
Journal:  J Am Chem Soc       Date:  2002-05-08       Impact factor: 15.419

7.  Total synthesis and structure-activity investigation of the marine natural product neopeltolide.

Authors:  Daniel W Custar; Thomas P Zabawa; John Hines; Craig M Crews; Karl A Scheidt
Journal:  J Am Chem Soc       Date:  2009-09-02       Impact factor: 15.419

8.  Pyran annulation: asymmetric synthesis of 2,6-disubstituted-4-methylene tetrahydropyrans.

Authors:  Gary E Keck; Jonathan A Covel; Tobias Schiff; Tao Yu
Journal:  Org Lett       Date:  2002-04-04       Impact factor: 6.005

Review 9.  Function-oriented synthesis, step economy, and drug design.

Authors:  Paul A Wender; Vishal A Verma; Thomas J Paxton; Thomas H Pillow
Journal:  Acc Chem Res       Date:  2007-12-27       Impact factor: 22.384

10.  Total synthesis and structural revision of the marine macrolide neopeltolide.

Authors:  Daniel W Custar; Thomas P Zabawa; Karl A Scheidt
Journal:  J Am Chem Soc       Date:  2008-01-23       Impact factor: 15.419

View more
  3 in total

1.  Toward the Ideal Synthesis and Transformative Therapies: The Roles of Step Economy and Function Oriented Synthesis.

Authors:  Paul A Wender
Journal:  Tetrahedron       Date:  2013-06-07       Impact factor: 2.457

2.  Lead Diversification through a Prins-Driven Macrocyclization Strategy: Application to C13-Diversified Bryostatin Analogues.

Authors:  Paul A Wender; Kelvin L Billingsley
Journal:  Synthesis (Stuttg)       Date:  2013       Impact factor: 3.157

3.  Atom economical, one-pot, three-reaction cascade to novel tricyclic 2,4-dihydro-1H-benzo[f]isochromenes.

Authors:  Robert J Hinkle; Shane E Lewis
Journal:  Org Lett       Date:  2013-08-01       Impact factor: 6.005

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.